Coherus Oncology Inc.
CHRS | NASDAQ
$1.37
+$0.02 (+1.48%)
At close: Sep 21, 2026, 4:00 PM ET
$1.42
+$0.05 (+3.94%)
Pre-market:
Sep 22, 2026, 8:46 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 42.17M | 266.96M | 257.24M | 211.04M | 326.55M | 475.82M |
Cost of Revenue | 17.74M | 117.55M | 158.99M | 70.08M | 57.59M | 37.67M |
Gross Profit | 24.43M | 149.41M | 98.25M | 140.96M | 268.96M | 438.16M |
Operating Income | -179.53M | -111.67M | -203.2M | -256.88M | -263.86M | 156.32M |
Interest Income | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -183.12M | 28.51M | -238.27M | -291.75M | -287.1M | 135.71M |
Net Income | -170.29M | 28.51M | -237.89M | -291.75M | -287.1M | 132.24M |
Selling & General & Admin | 99M | 150.44M | 185.62M | 198.48M | 169.71M | 139.08M |
Research & Development | 104.96M | 93.34M | 109.44M | 199.36M | 363.11M | 142.76M |
Other Expenses | n/a | 17.3M | 6.4M | n/a | n/a | n/a |
Operating Expenses | 203.97M | 261.07M | 301.45M | 397.84M | 532.82M | 281.84M |
Interest Expense | 9M | 27.16M | 40.54M | 32.47M | 22.96M | 21.17M |
Selling & Marketing Expenses | n/a | 10.9M | 10.9M | 10.5M | 8.7M | 3.8M |
Cost & Expenses | 221.71M | 378.63M | 460.44M | 467.92M | 590.41M | 319.51M |
Income Tax Expense | n/a | n/a | -380K | n/a | n/a | 3.46M |
Shares Outstanding (Basic) | 120.37M | 114.55M | 94.16M | 77.63M | 75.45M | 71.41M |
Shares Outstanding (Diluted) | 120.37M | 114.83M | 94.16M | 77.63M | 75.45M | 83.49M |
EPS (Basic) | -1.45 | 0.25 | -2.53 | -3.76 | -3.81 | 1.85 |
EPS (Diluted) | -1.45 | 0.25 | -2.53 | -3.76 | -3.81 | 1.62 |
EBITDA | -170.2M | 60.94M | -193.94M | -255.58M | -260.69M | 161.84M |
EBIT | -174.12M | 55.67M | -197.73M | -259.28M | -264.14M | 156.87M |
Depreciation & Amortization | 3.92M | 5.28M | 3.79M | 3.7M | 3.45M | 4.97M |
Add to Watchlist
Select watchlists to add or remove CHRS